Core Viewpoint - The company, Hangzhou Biotest Biotechnology Co., Ltd., is preparing for its third-quarter performance briefing scheduled for November 13, 2025, to provide insights into its operational results and financial status for the third quarter of 2025 [7][8]. Financial Data - The financial report for the third quarter of 2025 has not been audited [3]. - The report indicates that the company will implement a capital reserve transfer of 42,666,667 shares to shareholders, with a distribution of 4 shares for every 10 shares held, effective June 2025 [3]. Shareholder Information - The company assures that the quarterly report is accurate and complete, with no false records or significant omissions [2][5]. - There are no changes reported in the top ten shareholders or the status of shares available for lending [5][6]. Investor Engagement - The company is actively seeking questions from investors ahead of the performance briefing, allowing them to submit inquiries from November 6 to November 12, 2025 [10][13]. - The briefing will be held online, enabling real-time interaction between the company and investors [11][12]. Meeting Details - The performance briefing is set for November 13, 2025, from 9:00 AM to 10:00 AM, hosted on the Shanghai Stock Exchange Roadshow Center [11][12]. - Key personnel attending the meeting include the Chairman, General Manager, and Financial Director, among others [9].

Core Insights - 博拓生物 reported a total operating revenue of 308 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 20.76% [1] - The net profit attributable to shareholders of the parent company was 22.26 million yuan, down 75.04% year-on-year [1] - The basic earnings per share stood at 0.14 yuan [1]

证券代码：688767 证券简称：博拓生物 公告编号：2025-042 杭州博拓生物科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要提示： 上海证券交易所上证路演中心上海证券交易所上证路演中心 投资者可于 2025 年 11 月 6 日（星期四）至 11 月 12 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir.secretary@biotests.com.cn 进行提问，公司将在说明会上对投资者普遍关 注的问题进行回答。 一、说明会类型 杭州博拓生物科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日在上海证券交易所网站（www.sse.com.cn）披露公司 2025 年第三季度报告， 为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况， 公司计划于 2025 年 11 月 13 日上午 9:00-10:00 举行 2025 年第三季度业绩说明 会，就投资者关 ...

杭州博拓生物科技股份有限公司 2025 年第三季度报告 杭州博拓生物科技股份有限公司2025 年第三季度报告 证券代码：688767 证券简称：博拓生物 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 1 / 16 杭州博拓生物科技股份有限公司2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 | | | | 单位：元 | 币种：人民币 | | --- | --- | --- | --- | --- | | | | 本报告期比 | | 年初至报告期 | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | ...

Core Insights - The company reported a third-quarter revenue of 105 million, representing a decline of 13.84% [1] - The net profit for the third quarter was 9.86 million, down 42.12% [1] - For the first three quarters, the total revenue was 308 million, a decrease of 20.76% [1] - The net profit for the first three quarters was 22.26 million, reflecting a significant drop of 75.04% [1] Financial Performance - Third-quarter revenue: 105 million, down 13.84% [1] - Third-quarter net profit: 9.86 million, down 42.12% [1] - Year-to-date revenue (first three quarters): 308 million, down 20.76% [1] - Year-to-date net profit (first three quarters): 22.26 million, down 75.04% [1]

Group 1 - The core viewpoint of the news is that Botao Bio has seen a stock price increase of 5.46%, reaching 46.20 CNY per share, with a total market capitalization of 6.899 billion CNY [1] - Botao Bio, established on November 28, 2008, specializes in the research, production, and sales of POCT diagnostic reagents, with 100% of its revenue derived from POCT products [1] Group 2 - According to data, the Fuqua Fund holds a significant position in Botao Bio, with 613,800 shares representing 4.27% of the fund's net value, making it the ninth-largest holding [2] - The Fuqua Fund has achieved a year-to-date return of 64.11%, ranking 525 out of 8,155 in its category, and a one-year return of 63.45%, ranking 484 out of 8,031 [2] Group 3 - The fund managers of Fuqua Fund are Yang Dong and Meng Hao, with Yang having a tenure of 10 years and 76 days, and Meng having a tenure of 3 years and 278 days [3] - Yang's fund has a total asset size of 9.809 billion CNY, with the best return during his tenure being 329.8% and the worst being -38.34% [3] - Meng's fund has a total asset size of 4.565 billion CNY, with the best return during his tenure being 40.12% and the worst being -2.59% [3]

Market Performance - The medical device sector increased by 1.01% on October 21, with Botao Bio leading the gains [1] - The Shanghai Composite Index closed at 3916.33, up 1.36%, while the Shenzhen Component Index closed at 13077.32, up 2.06% [1] Top Gainers - Botao Bio (688767) closed at 43.39, up 8.12% with a trading volume of 50,200 shares and a transaction value of 216 million [1] - Xiangsheng Medical (688358) closed at 34.93, up 6.62% with a trading volume of 45,600 shares and a transaction value of 157 million [1] - Hualan Biological (301093) closed at 39.30, up 6.53% with a trading volume of 57,500 shares and a transaction value of 223 million [1] Top Losers - Jinhao Medical (920925) closed at 31.85, down 2.24% with a trading volume of 11,900 shares and a transaction value of 37.83 million [2] - Toukeng Life (300642) closed at 26.75, down 2.01% with a trading volume of 162,300 shares and a transaction value of 44.4 million [2] - Maillande (688273) closed at 40.48, down 1.99% with a trading volume of 22,300 shares and a transaction value of 90.15 million [2] Capital Flow - The medical device sector experienced a net outflow of 229 million from institutional investors and 168 million from retail investors, while retail investors saw a net inflow of 397 million [2][3] - Notable capital inflows included Xinhua Medical with a net inflow of 24.93 million from institutional investors [3] - Hualan Biological had a net inflow of 20.37 million from institutional investors, despite a net outflow from retail investors [3]

Core Viewpoint - The flu-related stocks experienced a significant surge on October 21, with notable increases in companies such as Te Yi Pharmaceutical, Jinshi Yao, and Hualan Vaccine, driven by rising flu activity in southern China and predictions of an earlier flu season this year [1][4]. Group 1: Stock Performance - Te Yi Pharmaceutical reached a trading limit with a price of 10.27, reflecting a 9.96% increase [2] - Jinshi Yao saw a price increase to 11.73, marking a 15.11% rise [2] - Hualan Vaccine's stock rose to 22.15, showing an 11.87% increase [2] - New Ganjing's stock price increased to 23.72, with a rise of 11.41% [2] - Other companies like Hengdi Pharmaceutical and Xiangrikui also followed the upward trend [1]. Group 2: Flu Activity and Predictions - The China CDC reported an increase in flu activity in southern provinces, indicating a potential early onset of the flu season this year [4] - Experts noted that the predominant flu strain this year is H3N2, differing from last year's H1N1 strain, which may lead to lower immunity levels in the population [5]. Group 3: Vaccination Recommendations - Vaccination is emphasized as the most effective method to prevent flu and reduce severe cases, with recommendations for individuals to get vaccinated between September and November [8] - The flu vaccine needs to be administered annually due to the rapid mutation of the virus, ensuring protection against the current year's strains [8][9]. - High-risk groups, including children under 5, the elderly, and individuals with chronic health conditions, are advised to prioritize vaccination [12].

Core Viewpoint - The article highlights the rising flu activity in southern China, with predictions of an earlier flu season this year compared to last, primarily driven by the different circulating strain, H3N2, which the public has lower immunity against [2][3]. Group 1: Flu Activity and Strain Information - The current flu season is characterized by the predominance of the H3N2 strain, contrasting with last year's H1N1 strain, indicating a need for heightened awareness due to lower public immunity [3]. - Clinical symptoms of H3N2 include high fever, cough, sore throat, body aches, fatigue, and headache, which are similar to other flu strains [3]. Group 2: Vaccination Recommendations - Vaccination is emphasized as the most effective method to prevent flu and reduce severe cases, with the recommended vaccination period being from September to November to ensure immunity before peak season [5]. - Annual vaccination is necessary due to the rapid mutation of flu viruses, which may differ from year to year, thus requiring updated protection [6]. - High-risk groups, including children under 5, the elderly over 65, pregnant women, and those with chronic health conditions, are advised to receive vaccinations promptly [10]. Group 3: Vaccine Types and Administration - The available flu vaccines in China include inactivated (split) vaccines (trivalent/quadrivalent), inactivated (subunit) vaccines (trivalent/quadrivalent), and live attenuated vaccines (trivalent, nasal spray) [8]. - The difference between trivalent and quadrivalent vaccines lies in the number of virus strains they protect against, with quadrivalent covering an additional B strain, although the practical effectiveness may not differ significantly [8].

Group 1 - The core viewpoint of the news is that Botao Bio has seen a stock price increase of 5.01%, reaching 42.14 CNY per share, with a total market capitalization of 6.293 billion CNY [1] - Botao Bio, established on November 28, 2008, specializes in the research, production, and sales of POCT diagnostic reagents, with 100% of its revenue derived from POCT products [1] - The trading volume for Botao Bio was 30.6043 million CNY, with a turnover rate of 0.49% [1] Group 2 - According to data, Guangfa Fund's Guangfa Value Core Mixed A Fund (010377) increased its holdings in Botao Bio by 1.5021 million shares in the second quarter, now holding 4.236 million shares, which is 2.84% of the circulating shares [2] - The fund has achieved a year-to-date return of 55.31%, ranking 428 out of 8162 in its category, and a one-year return of 62.05%, ranking 296 out of 8024 [2] - The fund manager, Wu Yuanyi, has a tenure of 5 years and 23 days, with the fund's total asset size at 20.478 billion CNY [2] Group 3 - The Guangfa Value Core Mixed A Fund (010377) holds Botao Bio as its eighth-largest position, with 4.236 million shares representing 2.75% of the fund's net value [3] - The estimated floating profit from this position is approximately 8.5144 million CNY [3]